Lindsey George: Understanding the Enhanced Activity of FVIII Aurora
Lindsey George, Assistant Professor of Pediatrics at University of Pennsylvania, Director of Clinical In Vivo Gene Therapy at Children’s Hospital of Philadelphia, shared on LinkedIn about a recent article she and her colleagues co-authored, published in Blood, adding:
”Congratulations Johnathan Morris!
This manuscript describes the underlying mechanism of FVIII Aurora (FVIII-R571S), which has 10–20-fold higher affinity for FIXa over FVIII-WT and FIXa-dependent reduced inactivation by A2-domain dissociation and APC cleavage.”
Title: Factor VIII Aurora: A Naturally Occurring Gain of Function FVIII Variant with Enhanced FIXa Affinity
Authors: Johnathan J. Morris, Robert J Davidson, Connor T. Watson, Lindsey A. George
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question